Previous articles have also recommended that randomized controlled trials be conducted to assess the surgical safety, patient reported outcomes (PROs), and oncologic outcomes of RNSM and thus evaluate its clinical role in treating BRCA1/2 carriers and patients with breast cancer [17, 18]. The gene discussed is BRCA1; the disease is breast carcinoma.